Hepatocellular Regeneration and Necrosis Markers in Chronic HCV Patients under Sofosbuvir-Based Regimen
Alnoby, A., Ali, A., yassin, A., Fayed, H., Mahmoud, H. (2021). Hepatocellular Regeneration and Necrosis Markers in Chronic HCV Patients under Sofosbuvir-Based Regimen. EKB Journal Management System, 4(2), 141-149. doi: 10.21608/svuijm.2020.47893.1023
Amr Alnoby; Abdallah Elaiw Mohamed Ali; Ayman S. yassin; Hanan Mahmoud Fayed; Hasan Sedeek Mahmoud. "Hepatocellular Regeneration and Necrosis Markers in Chronic HCV Patients under Sofosbuvir-Based Regimen". EKB Journal Management System, 4, 2, 2021, 141-149. doi: 10.21608/svuijm.2020.47893.1023
Alnoby, A., Ali, A., yassin, A., Fayed, H., Mahmoud, H. (2021). 'Hepatocellular Regeneration and Necrosis Markers in Chronic HCV Patients under Sofosbuvir-Based Regimen', EKB Journal Management System, 4(2), pp. 141-149. doi: 10.21608/svuijm.2020.47893.1023
Alnoby, A., Ali, A., yassin, A., Fayed, H., Mahmoud, H. Hepatocellular Regeneration and Necrosis Markers in Chronic HCV Patients under Sofosbuvir-Based Regimen. EKB Journal Management System, 2021; 4(2): 141-149. doi: 10.21608/svuijm.2020.47893.1023

Hepatocellular Regeneration and Necrosis Markers in Chronic HCV Patients under Sofosbuvir-Based Regimen

SVU-International Journal of Medical Sciences
Article 14, Volume 4, Issue 2, July 2021, Page 141-149  XML PDF (240.23 K)
Document Type: Original research articles
DOI: 10.21608/svuijm.2020.47893.1023
View on SCiNiTO View on SCiNiTO
Authors
Amr Alnoby email orcid 1; Abdallah Elaiw Mohamed Ali1; Ayman S. yassin2; Hanan Mahmoud Fayedorcid 1; Hasan Sedeek Mahmoud3
1Chemical and Clinical pathology Department, Faculty of Medicine, South Valley University, Qena, Egypt
2Microbiology and Immunology Department, Faculty of Medicine, Al-Azhar University, Assiut branch, Assiut, Egypt
3Tropical Medicine and Gastroenterology Department, Faculty of medicine, South Valley University, Qena, Egypt.
Abstract
Objectives: To evaluate noninvasive fibrosis markers, retinol binding protein 4 (RBP4), and alpha-feto protein (AFP) in foreseeing liver fibrosis in persistent hepatitis C patients and their correlations with Fibroscan.
Materials and Method: Fifty naive CHC patients and 20 healthy age and sex-matched subjects as controls were included. Blood samples and fibroscan obtained before and 3 months after treatment with DAAs for CBC, INR, and Liver function tests, RBP4, AFP and different fibrosis markers as APRI, CDS, FIB-4, GUCI, Lok index.
Results: All patients achieved SVR (12 weeks) with an change of liver function and decrease of liver fibrosis as measured by Fibroscan. The Fib-4 score gave the best performance and diagnostic accuracy for the prediction of the presence of significant fibrosis, then (APRI and GUCI) followed by the CDC and LOK index; and lastly RBP4 as they were efficient to differentiate significant fibrosis (moderate and severe) liver scarring (F2-F3) from mild fibrosis (F0-F1). However; the accuracy of RBP4 improved with a higher fibrosis grade and thus can differentiate the presence or absence of severe (F3-F4) from mild & moderate (F1-F2) liver scarring with 93.75% for PPV and NPV but with a poor prediction of the absence of significant fibrosis (F1 versus F2–F3), while LOK score was excellent in the prediction of the absence of significant fibrosis (F1 versus F2–F3).
Conclusions: FIB-4, APRI, GUCI, CDS, and Lok index were accurate to predict the fibrosis grade in CHC patients, correlated with hepatic injury and can assess DAAs treatment success.
Keywords
HCV; markers of hepatic regeneration and necrosis; Sofosbuvir
Statistics
Article View: 403
PDF Download: 304